Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2017-12-14 |
OSE Immunotherapeutics (France) |
€398,000 |
grant |
FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France |
Cancer - Oncology |
Grant |
2017-12-13 |
Myonexus Therapeutics (USA - OH) |
$2.5 million |
seed financing round |
The Jain Foundation (USA) GFB ONLUS (USA) Rev1 Ventures (USA - OH) investors from the LGMD community. |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Financing round |
2017-12-12 |
NorthSea Therapeutics (The Netherlands) |
€ 25 million |
series A financing round |
Forbion Capital Partners (The Netherlands) BioGeneration Ventures (The Netherlands) Novo Seeds (Denmark) New Science Ventures (USA - NY) |
Hepatic diseases - Liver diseases - Inflammatory diseases |
Series A financing round |
2017-12-12 |
bluebird bio (USA - MA) |
$600 million |
private placement |
|
Rare diseases - Genetic diseases |
Private placement |
2017-12-11 |
Viking Therapeutics (USA - PA) |
$14.8 million |
private placement |
|
Endocrinological diseases - Metabolic diseases |
Private placement |
2017-12-05 |
Cell and Gene Therapy Catapult (UK) Oxford MEStar (UK) AK (Suzhou) Biomedical (Chinaà |
undisclosed |
grant |
Innovate UK-Jiangsu Industrial Challenge Programme (UK - China) |
Technology - Services |
Grant |
2017-12-05 |
Grifols (Spain) |
€ 85 million |
loan |
European Investment Bank (EIB) |
Rare diseases - Genetic diseases |
Loan |
2017-12-04 |
Harmonic Pharma (France) |
undisclosed |
capital increase |
Novacap (France) |
Technology - Services |
Capital increase |
2017-11-30 |
Chordia Therapeutics (Japan) |
¥1.2 billion ($ 11 million) |
series A financing round |
Takeda Pharmaceutical (Japan) Kyoto University Innovation Capital (Japan) Mitsubishi UFJ capital (Japan) SMBC venture (Japan) |
Cancer - Oncology |
Series A financing round |
2017-11-29 |
Y-mAbs Therapeutics (US - NY) |
$80 million |
private placement |
HBM Healthcare Investments (Switzerland), current shareholders, Sofimac Partners (France) Scopia Capital Management (US - NY) |
Cancer - Oncology |
Private placement |
2017-11-29 |
Y-mAbs Therapeutics (USA - NY) |
$80 million |
private placement |
HBM Healthcare Investments (Switzerland) existing investors Sofinnova Ventures (USA) Scopia Capital Management (USA) |
Cancer - Oncology |
Private placement |
2017-11-17 |
VBL Therapeutics/Vascular Biogenics (Israel) |
|
financing round |
|
Cancer - Oncology |
Financing round |
2017-11-15 |
Erytech Pharma |
$130 million |
capital increase |
|
Cancer - Oncology - Rare diseases |
Capital increase |
2017-11-10 |
Transgene (France) |
€ 14.4 million |
capital increase |
qualified U.S. and European institutional investors including Institut Mérieux (France) and Dassault Belgique Aviation |
Cancer - Oncology - Infectious diseases |
Capital increase |
2017-11-08 |
InflaRX (Germany) |
$100 million |
IPO |
|
Inflammatory diseases |
IPO |
2017-11-06 |
Nouscom (Switzerland) |
€42 Million |
series B financing round |
Abingworth (UK) 5AM Ventures (USA - CA) LSP (The Netherlands) Versant Ventures. (USA - CA) |
Cancer - Oncology |
Series B financing round |
2017-11-02 |
Mina Therapeutics (UK) LGC LINK (UK) |
£400,000 |
grant |
Innovate UK (UK) |
Liver diseases - Hepatic diseases |
Grant |
2017-11-02 |
20Med Therapeutics (NL) |
|
|
Twente Technology Fund (TTF) (NL), Oost NL (NL), |
|
Restructuring |
2017-11-02 |
20Med Therapeutics (NL) |
undisclosed |
financing round |
Twente Technology Fund (TTF) (NL), Oost NL (NL) through regional innovation fund Innovatiefonds Twente (IFT) |
Technology - Services |
Financing round |
2017-10-24 |
Immune Design (USA - MA) |
$86.6 million |
private placement |
|
Cancer - Oncology |
Private placement |